Synthetic biology startups face a ‘reckoning’.

The article examines the recent struggles of major synthetic biology companies, which have faced financial difficulties and bankruptcy due to overambitious projects and lack of focus. Topics discussed include the challenges faced by these firms in scaling up non-pharmaceutical products, the success of companies concentrating on pharmaceuticals and specialized markets, and the potential future growth of synthetic biology in bio-based materials and innovative applications.